Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07340541CT.gov Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03032406CT.gov CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02269670CT.gov Phase II Study of Everolimus Beyond Progression | — | Terminated | — | — | — |
NCT02273752CT.gov Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | — | Terminated | — | — | — |
NCT02120469CT.gov Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02152943CT.gov Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | — | Completed | — | — | — |
NCT01783756CT.gov Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | — | Completed | — | — | — |
NCT01805271CT.gov Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | UNC Lineberger Comprehensive Cancer Center | P3 | BB · 65 |
| Trastuzumab | SWOG Cancer Research Network | P4 | BBB |
| Tamoxifen | Dartmouth-Hitchcock Medical Center | P4 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P3 | BBB |
| Trastuzumab Deruxtecan | SWOG Cancer Research Network | P4 | BBB |
| Zoledronate | Washington University School of Medicine | P4 | BBB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P3 | BBB |
| Dexasone | Tianjin Medical University Cancer Institute and Hospital | P4 | BBB |
| Letrozole | OHSU Knight Cancer Institute | P4 | BBB |
+42 more in the Breast Carcinoma cohort
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Everolimus in Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →